Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now leads a fast-growing market for GLP-1 and metabolic therapies.

Modern weight-loss medications like Ozempic and Mounjaro, originally for diabetes, are gaining attention for their ability to ...

Eli Lilly’s anti-obesity and diabetes drug Mounjaro has become the No. 1 brand by sales value in the Indian Pharmaceutical Market (IPM) for the first time in the month of October. The drug clocked ...

Wegovy’s key competitor is Eli Lilly’s GLP-1 drug Mounjaro (tirzepatide), which became India’s top-selling medicine in ...

Eli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps control blood sugar and slows digestion. Demand for such ...

Weight-loss drug rakes in ₹333 cr in cumulative sales since launch in March this year, leaving rival Wegovy behind ...

Unsupervised GLP-1 use rises in India as structured, doctor-led platforms like Early.Fit push for safer, science-backed ...

Eli Lilly's diabetes and obesity drug Mounjaro (Tirzepatide) has become India's top-selling drug by value for October 2025, ...

Wegovy’s price cut follows Mounjaro’s success in IndiaIndia key market for Novo Nordisk and Eli Lilly’s obesity drugsWegovy’s ...

HYDERABAD, Nov 7 (Reuters) - Eli Lilly's (LLY.N), opens new tab weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, overtaking GSK's (GSK.L), opens ...

Eli Lilly's ( LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, surpassing GSK's ( GSK) antibiotic, Augmentin, a Reuters report said.